PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Cadilha, B.L.* ; Benmebarek, M.R.* ; Dorman, K.* ; Oner, A.* ; Lorenzini, T.* ; Obeck, H.* ; Vänttinen, M.* ; Pilato, M.D.* ; Pruessmann, J.N.* ; Stoiber, S.* ; Huynh, D.* ; Märkl, F.* ; Seifert, M.* ; Manske, K.* ; Suarez-Gosalvez, J.* ; Zeng, Y.* ; Lesch, S.* ; Karches, C.H.* ; Heise, C.* ; Gottschlich, A.* ; Thomas, M. ; Marr, C. ; Zhang, J.* ; Pandey, D.* ; Feuchtinger, T.* ; Subklewe, M.* ; Mempel, T.R.* ; Endres, S.* ; Kobold, S.

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors.

Sci. Adv. 7:eabi5781 (2021)
Verlagsversion Forschungsdaten DOI PMC
Open Access Gold
Creative Commons Lizenzvertrag
CAR T cell therapy remains ineffective in solid tumors, due largely to poor infiltration and T cell suppression at the tumor site. T regulatory (Treg) cells suppress the immune response via inhibitory factors such as transforming growth factor–β (TGF-β). Treg cells expressing the C-C chemokine receptor 8 (CCR8) have been associated with poor prognosis in solid tumors. We postulated that CCR8 could be exploited to redirect effector T cells to the tumor site while a dominant-negative TGF-β receptor 2 (DNR) can simultaneously shield them from TGF-β. We identified that CCL1 from activated T cells potentiates a feedback loop for CCR8+ T cell recruitment to the tumor site. This sustained and improved infiltration of engineered T cells synergized with TGF-β shielding for improved therapeutic efficacy. Our results demonstrate that addition of CCR8 and DNR into CAR T cells can render them effective in solid tumors.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
14.136
3.445
7
28
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Wissenschaftlicher Artikel
Schlagwörter Growth-factor-beta; Receptor; Driven
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2375-2548
e-ISSN 2375-2548
Zeitschrift Science Advances
Quellenangaben Band: 7, Heft: 24, Seiten: , Artikelnummer: eabi5781 Supplement: ,
Verlag American Association for the Advancement of Science (AAAS)
Verlagsort Washington, DC [u.a.]
Begutachtungsstatus Peer reviewed
Institut(e) Unit for Clinical Pharmacology (KKG-EKLiP)
Institute of Computational Biology (ICB)
POF Topic(s) 30203 - Molecular Targets and Therapies
30205 - Bioengineering and Digital Health
Forschungsfeld(er) Immune Response and Infection
Enabling and Novel Technologies
PSP-Element(e) G-522100-001
G-503800-001
Förderungen Ernst-Jung-Stiftung
Melanoma Research Alliance Grants
Marie-Sklodowska-Curie Program Training Network for the Immunotherapy of Cancer - H2020 Program of the European Union
Marie-Sklodowska-Curie Program Training Network for Optimizing Adoptive T Cell Therapy of Cancer - H2020 Program of the European Union
Hector foundation
Else Kroner-Fresenius-Stiftung
LMU Munich's Institutional Strategy LMUexcellent
Bundesministerium fur Bildung und Forschung Project Oncoattract
European Research Council
German Research Foundation (DFG)
NIH
Fritz-Bender Foundation
European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program
Volkswagen Foundation (project OntoTime)
Jose-Carreras Foundation
Deutsche Gesellschaft fur Immun-und Targeted-therapie
German Cancer Aid
International Doctoral Program i-Target: Immunotargeting of Cancer - Elite Network of Bavaria
DOI 10.1126/sciadv.abi5781
WOS ID WOS:000659923500013
Scopus ID 85107474573
PubMed ID 34108220
Erfassungsdatum 2021-07-06
[➜Korrektur melden]